Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Once weekly subcutaneous injection of TransCon hGH
Once weekly of TransCon hGH · 1 trial · 5 indications
Annualized height velocity (AHV) at 52 weeks for weekly lonapegsomatropin (TransCon hGH) and daily hGH treatment groups
| Arm | Type | Description |
|---|---|---|
| TransCon hGH | EXPERIMENTAL | Once weekly subcutaneous injection of TransCon hGH |
| human growth hormone (Genotropin) | ACTIVE_COMPARATOR | Once daily subcutaneous injection of Genotropin |
| Name | Type | Description |
|---|---|---|
| Once weekly subcutaneous injection of TransCon hGH | DRUG | Once weekly subcutaneous injection |
| Once daily subcutaneous injection of Genotropin | DRUG | Once daily subcutaneous injection |
Inclusion Criteria: * Prepubertal children with GHD (either isolated or as part of a multiple pituitary hormone deficiency) in Tanner stage 1 (Tanner 1982) aged: * Boys: 3-12 years, inclusive * Girls: 3-11 years, inclusive * Impaired height (HT) defined as at least 2.0 standard deviations (SD)...
Once weekly TransCon hGH is an investigational long-acting human growth hormone therapy developed by Ascendis Pharma A/S for pediatric growth hormone deficiency. It is designed to be given as a once weekly subcutaneous injection, compared with daily injections of standard human growth hormone. It has completed a Phase 3 clinical trial in children with growth hormone deficiency.
Once weekly TransCon hGH is being developed for the treatment of pediatric growth hormone deficiency, a condition in which children do not produce enough growth hormone. The goal of treatment is to support normal growth. It is investigational and has been studied in children aged 3 years and older.
Once weekly TransCon hGH is being developed by Ascendis Pharma A/S, which trades on the Nasdaq under the ticker ASND. The company is the sponsor of the clinical program evaluating the once weekly subcutaneous injection in pediatric growth hormone deficiency.
Once weekly TransCon hGH has completed a Phase 3 clinical trial in pediatric growth hormone deficiency. It is an investigational therapy and is not described as approved. The Phase 3 study, NCT02781727, has been completed and enrolled 162 participants.
Once weekly TransCon hGH has been studied in one Phase 3 trial, NCT02781727, titled a Phase 3 trial of the safety, tolerability and efficacy of TransCon hGH weekly versus daily hGH in children with growth hormone deficiency. The trial was completed, enrolled 162 participants, and was active-controlled with randomization.
Yes. Once weekly TransCon hGH and once weekly subcutaneous injection of TransCon hGH refer to the same investigational product from Ascendis Pharma A/S. The longer name describes the route of administration, a subcutaneous injection given once weekly, while the shorter name is the common shorthand for the same therapy.